Information Provided By:
Fly News Breaks for March 20, 2017
PRAH
Mar 20, 2017 | 07:07 EDT
SunTrust analyst Sandy Draper identifies PRA Health as his favorite late-stage contract research organization, or CRO. The analyst expects the company's partnerships to drive double digit percentage revenue growth through at least 2018. Draper says that the company has high quality bookings, and he raised his price target on the shares to $72 from $70. He keeps a Buy rating on the stock.
News For PRAH From the Last 2 Days
PRAH
Aug 16, 2017 | 16:34 EDT
Raymond James analyst Michael Baker initiated PRA Health with an Outperform and an $89 price target telling investors it is one of the fasts growing contract research organizations, or CRO, that offers clients an innovative approach to to clinical development that has gained significant traction among large pharma client segment. Further, he expects two recent strategic partnerships, strong bookings growth, and peers tied up in large-scale M&A should translate to higher 2018 revenue and EPS than consensus expects.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.